| Species |
Human |
| Protein Construction |
BAFF-R (Met1-Gly76)
Accession # Q96RJ3 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by its ability to block BAFF induced mouse splenocyte survival is 1.0-5.0 μg/ml in the presence of 1.0 μg/ml of rHuBAFF. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
7.8 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 8.0, 500 mM NaCl. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
BAFF Receptor (BAFF-R), a member of the TNFR superfamily, is highly expressed in spleen, lymph node, and resting B cells and to some extent in activated B cells, resting CD4+ cells and peripheral blood leukocytes. BAFF-R is a type III transmembrane protein that binds with high specificity to BAFF (TNFSF13B). BAFF-R/BAFF signaling plays a critical role in B cell survival and maturation. |
| Synonyms |
BAFF Receptor; BLyS receptor 3; CD_antigen: CD268; |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
